Conning Inc. Vertex Pharmaceuticals Inc Transaction History

Conning Inc.

$2.8 Billion
Q3 2025

A detailed history of Conning Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Conning Inc. holds 1,544 shares of VRTX stock, worth $662,715. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,544

Previous 1,544 -0.0%

Holding current value

$662,715

Previous $687,000 12.08%

% of portfolio

0.02%

Previous 0.03%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 24, 2025	SELL	$421.16 - $509.5 $17,688 - $21,399	-42 Reduced 2.65%	1,544 $687,000
Q1 2025 Apr 28, 2025	BUY	$402.49 - $513.76 $69,228 - $88,366	172 Added 12.16%	1,586 $768,000
Q4 2024 Jan 28, 2025	SELL	$396.64 - $516.74 $35,300 - $45,989	-89 Reduced 5.92%	1,414 $569,000
Q3 2024 Oct 29, 2024	SELL	$460.0 - $505.78 $8,280 - $9,104	-18 Reduced 1.18%	1,503 $699,000
Q2 2024 Jul 26, 2024	BUY	$392.81 - $485.53 $12,962 - $16,022	33 Added 2.22%	1,521 $712,000
Q1 2024 Apr 26, 2024	SELL	$407.69 - $446.08 $16,307 - $17,843	-40 Reduced 2.62%	1,488 $621,000
Q4 2023 Jan 29, 2024	BUY	$343.0 - $410.68 $3,430 - $4,106	10 Added 0.66%	1,528 $621,000
Q3 2023 Oct 26, 2023	SELL	$338.18 - $362.46 $6,763 - $7,249	-20 Reduced 1.3%	1,518 $527,000
Q2 2023 Jul 21, 2023	SELL	$314.42 - $351.91 $73,888 - $82,698	-235 Reduced 13.25%	1,538 $541,000
Q1 2023 Apr 27, 2023	SELL	$283.23 - $323.1 $5,664 - $6,462	-20 Reduced 1.12%	1,773 $558,000
Q4 2022 Feb 07, 2023	SELL	$285.76 - $321.48 $2,286 - $2,571	-8 Reduced 0.44%	1,793 $517,000
Q3 2022 Oct 28, 2022	SELL	$273.83 - $305.53 $27,930 - $31,164	-102 Reduced 5.36%	1,801 $521,000
Q2 2022 Jul 20, 2022	SELL	$234.96 - $292.55 $5,169 - $6,436	-22 Reduced 1.14%	1,903 $536,000
Q1 2022 May 02, 2022	SELL	$221.42 - $260.97 $37,641 - $44,364	-170 Reduced 8.11%	1,925 $502,000
Q4 2021 Jan 27, 2022	SELL	$177.01 - $223.45 $70,626 - $89,156	-399 Reduced 16.0%	2,095 $460,000
Q3 2021 Nov 05, 2021	SELL	$181.39 - $202.99 $107,020 - $119,764	-590 Reduced 19.13%	2,494 $452,000
Q2 2021 Jul 29, 2021	SELL	$187.49 - $221.1 $56,809 - $66,993	-303 Reduced 8.95%	3,084 $622,000
Q1 2021 Apr 23, 2021	SELL	$207.02 - $241.31 $62,106 - $72,393	-300 Reduced 8.14%	3,387 $728,000
Q4 2020 Jan 28, 2021	SELL	$207.01 - $276.09 $3,105 - $4,141	-15 Reduced 0.41%	3,687 $871,000
Q3 2020 Oct 21, 2020	BUY	$255.65 - $303.1 $17,639 - $20,913	69 Added 1.9%	3,702 $1.01 Million
Q2 2020 Aug 07, 2020	SELL	$225.48 - $295.8 $57,271 - $75,133	-254 Reduced 6.53%	3,633 $1.06 Million
Q1 2020 Apr 29, 2020	BUY	$199.77 - $247.81 $1,398 - $1,734	7 Added 0.18%	3,887 $925,000
Q4 2019 Jan 29, 2020	BUY	$166.71 - $223.91 $6,668 - $8,956	40 Added 1.04%	3,880 $850,000
Q2 2019 Jul 25, 2019	SELL	$164.61 - $190.37 $256,626 - $296,786	-1,559 Reduced 28.88%	3,840 $704,000
Q1 2019 Apr 22, 2019	SELL	$163.73 - $194.7 $9,823 - $11,682	-60 Reduced 1.1%	5,399 $993,000
Q4 2018 Jan 29, 2019	SELL	$151.91 - $192.21 $74,435 - $94,182	-490 Reduced 8.24%	5,459 $905,000
Q3 2018 Oct 26, 2018	SELL	$167.73 - $192.74 $30,191 - $34,693	-180 Reduced 2.94%	5,949 $1.15 Million
Q2 2018 Jul 25, 2018	SELL	$145.72 - $169.96 $13,114 - $15,296	-90 Reduced 1.45%	6,129 $1.04 Million
Q1 2018 May 04, 2018	SELL	$151.6 - $177.13 $16,676 - $19,484	-110 Reduced 1.74%	6,219 $1.01 Million
Q4 2017 Jan 30, 2018	SELL	$137.28 - $155.55 $9,609 - $10,888	-70 Reduced 1.09%	6,329 $948,000
Q3 2017 Oct 20, 2017	BUY	$148.13 - $162.24 $947,883 - $1.04 Million	6,399	6,399 $973,000

Others Institutions Holding VRTX

# of Institutions

1,780

Shares Held

235M

Call Options Held

1.96M

Put Options Held

1.14M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $110B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Conning Inc., based on Form 13F filings with the SEC.

News

Stay updated on Conning Inc. with notifications on news.

Account